Stockscreener 앱 받기
2.7141
4.42%
0.1141
전일 마감가:
$2.60
열려 있는:
$2.6
하루 거래량:
309.59K
Relative Volume:
0.44
시가총액:
$155.57M
수익:
$70.00M
순이익/손실:
$22.37M
주가수익비율:
7.1349
EPS:
0.3804
순현금흐름:
$29.61M
1주 성능:
-7.02%
1개월 성능:
+13.60%
6개월 성능:
-25.00%
1년 성능:
+52.53%
1일 변동 폭
$2.58
$2.77
1주일 범위
$2.535
$2.94
52주 변동 폭
$1.46
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
명칭
Black Diamond Therapeutics Inc
전화
617-417-5868
주소
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.715 | 148.98M | 70.00M | 22.37M | 29.61M | 0.3804 |
VRTX
Vertex Pharmaceuticals Inc
|
427.40 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
708.35 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.97 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.93 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
299.09 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-11-18 | 재개 | Piper Sandler | Overweight |
| 2025-10-16 | 재개 | Stifel | Buy |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2024-07-31 | 개시 | Raymond James | Outperform |
| 2023-07-14 | 개시 | Piper Sandler | Overweight |
| 2023-06-30 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-03-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-03-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-01-07 | 개시 | Wedbush | Outperform |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-02-24 | 개시 | Canaccord Genuity | Buy |
| 2020-02-24 | 개시 | Cowen | Outperform |
| 2020-02-24 | 개시 | JP Morgan | Overweight |
| 2020-02-24 | 개시 | Jefferies | Buy |
모두보기
Black Diamond Therapeutics Inc 주식(BDTX)의 최신 뉴스
Implied volatility surging for Black Diamond Therapeutics stock options - MSN
HC Wainwright Issues Positive Forecast for BDTX Earnings - MarketBeat
Why is Black Diamond (BDTX) up 19.3% since last earnings report? - MSN
[ARS] Black Diamond Therapeutics, Inc. SEC Filing - Stock Titan
Black Diamond Therapeutics (BDTX) outlines 2026 virtual meeting and Say-on-Pay votes - Stock Titan
BDTX Maintained by BTIG -- Price Target Raised to $11.00 - GuruFocus
Black Diamond Therapeutics (NASDAQ:BDTX) Given New $11.00 Price Target at BTIG Research - MarketBeat
H.C. Wainwright Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Raises Target Price to $11 - Moomoo
Implied Volatility Surging for Black Diamond Therapeutics Stock Options - Zacks Investment Research
BDTX: What silevertinib data say about EGFR NSCLC upside - MSN
Will Upcoming Catalysts Help Black Diamond Investors Breathe Easy? - RTTNews
Black Diamond stock: Weighing catalysts vs. concentration - MSN
Jefferies Financial Group Upgrades Black Diamond Therapeutics (NASDAQ:BDTX) to Strong-Buy - MarketBeat
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize - TradingView
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right - Yahoo Finance
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks - TradingView
BlackDiamond (BDTX) Stock: Technical Momentum Review | Q4 2025: Earnings Fall ShortBuyback Report - Xã Châu Thành
BDTX (Black Diamond Therapeutics Inc.) shares rise nearly 8 percent even as fourth quarter 2025 earnings fall well below analyst estimates.Community Sell Signals - UBND thành phố Hải Phòng
Black Diamond Therapeutics Announces Multiple Presentations on Silevertinib at 2026 ASCO Annual Meeting - Quiver Quantitative
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting - ChartMill
Lung cancer drug data from Black Diamond gets ASCO oral slot - Stock Titan
BlackDiamond (BDTX) Stock Options Volume (Grinds Higher) 2026-04-20High Yield Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
BlackDiamond (BDTX) Stock: Why Day Traders Love It (+4.79%) 2026-04-18Social Momentum Signals - UBND thành phố Hải Phòng
Wedbush bullish on Black Diamond Therapeutics (BDTX) following progress in Silevertinib program - MSN
Black Diamond Sued Over Patented Cancer Drug Discovery Methods - Bloomberg Law News
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report? - Yahoo Finance
BlackDiamond (BDTX) Stock Adds to Position (Buying Pressure) 2026-04-15Momentum Picks - Cổng thông tin điện tử tỉnh Lào Cai
Trading Action: Will Black Diamond Therapeutics Inc benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - baoquankhu1.vn
Volatility Watch: Will Black Diamond Therapeutics Inc benefit from AI trends2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Black Diamond Therapeutics Receives 'Moderate Buy' Rating from Analysts - National Today
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Market Fear: Does Black Diamond Therapeutics Inc outperform in volatile marketsGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Invesco Senior Loan Fund's Black Diamond Therapeutics Inc(BDTX) Holding History - GuruFocus
Investment Recap: How does Black Diamond Therapeutics Inc score in quality rankingsWeekly Investment Summary & Long-Term Safe Return Strategies - baoquankhu1.vn
Risk Recap: Is Black Diamond Therapeutics Inc part of any ETFDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
BDTX: Insights from Silevertinib Data on EGFR NSCLC Growth Potential - Bitget
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026 - TradingView
Black Diamond Stock: Weighing Catalysts vs. Concentration - Yahoo Finance
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside - TradingView
Black Diamond Therapeutics Inc (BDTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.83%
2.04%
자본화:
|
볼륨(24시간):